A Phase 3 interventional study of DWP14012 20mg and Lansoprazole 15 mg in Peptic Ulcer, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-07-08.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Peptic Ulcer with a site in Korea, Republic of — 4 open to participants now, 5 under way, 3 of them phase 3. Peptic Ulcer · Korea, Republic of.
Among the 19 studies in Peptic Ulcer with a site in Korea, Republic of, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2021, is one of 7 in phase 3, and was the 14th registered.
146 studies on the registry are indexed under Peptic Ulcer; 25 are open to participants now.
Browse Peptic Ulcer studies →4 of the 19 studies in Peptic Ulcer with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Onconic Therapeutics Inc. · Sites in Korea, Republic of
Ages 19+
Duk-Woo Park, MD · Sites in Korea, Republic of
Ages 19+
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of, Indonesia
Ages 19+
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 18 Peptic Ulcer studies recruiting now, 11 (61%) set no upper age limit and 7 (39%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 423 is above the median of 165 across 105 interventional studies indexed under Peptic Ulcer.
Median enrollment 344 across the 16 interventional studies, 455 across the 3 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 19 have an industry lead sponsor. The 10 most frequent:
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Daewoong Pharmaceutical Co. LTD. has 3 studies filed under Peptic Ulcer — fewer than ten, so there is no comparison to draw.
3 of the studies in Peptic Ulcer with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06439563Phase 3Onconic Therapeutics Inc.Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers | 2027-08 |
| NCT06284876Phase 3Il-Yang Pharm. Co., Ltd.Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer | 2027-08-30 |
| NCT07558707Daewoong Pharmaceutical Co. LTD.Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies in Peptic Ulcer with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to demonstrate the preventive effect of DWP14012 20 mg for peptic ulcer is non-inferior to that of Lansoprazole 15 mg in terms of prevention of peptic ulcer and confirm the safety of DWP14012 20 mg.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
orally, once daily
Drug: DWP14012 20mg · Drug: Lansoprazole 15 mg placebo
orally, once daily
Drug: Lansoprazole 15 mg · Drug: DWP14012 20mg placebo
DWP14012 20mg, tablet, orally, once daily for up to 24 weeks
Lansoprazole 15mg capsule, orally, once daily for up to 24 weeks
DWP14012 20mg placebo-matching tablet, orally, once daily for up to 24 weeks
Lansoprazole 15mg placebo matching capsule, orally, once daily for up to 24 weeks
Proportion of subjects who develop peptic ulcer by Week 24 as assessed by investigator
Time frame: at 24 weeks
Proportion of subjects who develop peptic ulcer by Week 12 as assessed by investigator
Time frame: at 12 weeks
Proportion of subjects with endoscopic gastric or duodenal bleeding** by Week 12 and Week 24
Time frame: at 12, 24 weeks
Ran from May 2021 to primary completion in Nov 2023, 30 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fexuprazan
Daewoong Pharmaceutical Co. LTD. →